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Abstract
Background:  Malaria-endemic countries are switching antimalarial drug policy from cheap
ineffective monotherapies to artemisinin combination therapies (ACTs) for the treatment of
Plasmodium falciparum malaria and the global community are considering setting up a global subsidy
to fund their purchase. However, in order to ensure that ACTs are correctly used and are
accessible to the poor and remote communities who need them, specific interventions will be
necessary and the additional costs need to be considered.
Methods: This paper presents an incremental cost analysis of some of these interventions in
Cambodia, the first country to change national antimalarial drug policy to an ACT of artesunate
and mefloquine. These costs include the cost of rapid diagnostic tests (RDTs), the cost of blister-
packaging the drugs locally and the costs of increasing access to diagnosis and treatment to remote
communities through malaria outreach teams (MOTs) and Village Malaria Workers (VMW).
Results: At optimum productive capacity, the cost of blister-packaging cost under $0.20 per
package but in reality was significantly more than this because of the low rate of production. The
annual fixed cost (exclusive of RDTs and drugs) per capita of the MOT and VMW schemes was
$0.44 and $0.69 respectively. However because the VMW scheme achieved a higher rate of
coverage than the MOT scheme, the cost per patient treated was substantially lower at $5.14
compared to $12.74 per falciparum malaria patient treated. The annual cost inclusive of the RDTs
and drugs was $19.31 for the MOT scheme and $11.28 for the VMW scheme given similar RDT
positivity rates of around 22% and good provider compliance to test results.
Conclusion: In addition to the cost of ACTs themselves, substantial additional investments are
required in order to ensure that they reach the targeted population via appropriate delivery
systems and to ensure that they are used appropriately. In addition, differences in local conditions,
in particular the prevalence of malaria and the pre-existing infrastructure, need to be considered
in choosing appropriate diagnostic and delivery strategies.
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Background
Artemisinin combination therapies (ACTs) are now the
officially recommended treatment for Plasmodium falci-
parum malaria in most malaria-endemic countries [1-3].
However, there are significant challenges in the actual
implementation of this change in antimalarial drug pol-
icy. In the era of cheap monotherapies, namely chloro-
quine and sulphadoxine-pyrimethamine (SP), treatment
for malaria was largely based on inaccurate clinical diag-
nosis and often obtained by patients from sources outside
of the formal health sector. With ACTs currently costing
around five to 10 times more than the traditional mono-
therapies, there needs to be a radical change in the
approach to how they are funded and supplied in order to
ensure that they are accessible and affordable to those
who most need them. At a global level, support is gather-
ing for the setting up of the Affordable Medicines Facilities
-malaria, a global subsidy for ACTs, as recommended by
the Institute of Medicine report "Saving lives, buying
time" [4,5]. It is hoped that such a subsidy would enable
ACTs to flow through the private sector as well as the pub-
lic sector, to reach the poor and remote communities who
are most vulnerable and, if subsidized heavily enough,
displace monotherapies and sub-standard drugs. How-
ever, there is still significant uncertainty about how to best
maximize access, whilst limit the wastage and risks associ-
ated with widespread inappropriate use of ACTs by those
who do not have malaria [6,7]. Specific interventions to
target the most biologically and economically at-risk
include delivery mechanisms such as Village Malaria
Workers (VMWs) and the wider use of rapid diagnostic
tests (RDTs). Although the process and costs of policy
change itself has been described [3,8], there is little expe-
rience of nationwide implementation and the cost of
operationalizing such a policy change is largely unknown.
Cambodia was the first country to switch to a nation-wide
policy of artemisinin combination therapy (ACT) using
artesunate and mefloquine, for the first-line treatment of
P. falciparum malaria in 2000 [9]. As in many tropical
countries today, it was clear from the outset that there
were a number of obstacles to successful implementation.
These included the unavailability of any commercially
available co-formulated or co-packaged ACTs; the low uti-
lization of public health facilities in Cambodia; the high
usage of antimalarials without biological confirmation of
malaria; and the wide-spread availability of fake artesu-
nate and mefloquine [10,11]. In order to address these
problems, a number of innovative strategies were intro-
duced including the local blister-packaging of artesunate
and mefloquine in Phnom Penh, the deployment of
HRP2-based rapid diagnostic tests (RDTs), and in certain
areas, specific interventions to increase access to diagnosis
and treatment through social marketing, Village Malaria
Workers (VMWs) and malaria outreach teams (MOTs).
This study describes the incremental cost to the public sec-
tor of some of these interventions in order to inform the
decision-making process in other countries embarking on
the implementation of ACTs and feed into global advo-
cacy on funding ACT scale-up [12].
Interventions
Blister-packaged artesunate and mefloquine
When the decision was made to recommend artesunate
and mefloquine as the first-line treatment for uncompli-
cated P. falciparum malaria, there were no commercially
available co-formulated or co-blistered products, and no
local pharmaceutical companies with the capacity to pro-
duce blister-packages. However, it was felt that the blister
packaging was essential to ensure that the drugs were cor-
rectly prescribed by health providers, and correctly taken
by patients. In addition, in view of the prevalence of fake
drugs, it was felt that pre-packaging drugs would enable
both patients and health workers to be assured of drug
quality, as only drugs with internationally recognized
Good Manufacturing Practice (GMP) would be used. The
decision was therefore made to blister package artesunate
and mefloquine locally as a temporary measure. This was
done by the National Malaria Centre (CNM) with support
from World Health Organization (WHO). A room in the
Central Medical Stores building was renovated, new pack-
aging and printing machines were installed and staff given
appropriate training. Maximum production was esti-
mated at around 2,000 tablets/day or 40,000 blisters per
month. In reality only 56,794 packages were officially
produced in 2001[13].
The recommended regime was artesunate given over three
days (4 mg/kg/day) and mefloquine to be given as a split
dose on the first day (Table 1). The tablets were pre-pack-
aged in three different packages based on weight and age
as shown in Table 1. Children under six years of age were
recommended to receive five days of daily rectal artesu-
nate (but this is now being replaced with oral artesunate
and mefloquine). Packages of artesunate and mefloquine
were packaged for the public sector in plain boxes and
labelled with "A+M" and a warning of "not for sale". The
artesunate and mefloquine regimes for the two older age
groups were also made available in the private sector in
social marketing scheme that was initially piloted in two
districts, and then launched nationwide in March 2003.
The drugs were packaged in more attractive boxes and
sold to the private sector as "Malarine®" at a subsidized
price The packaging process has since been contracted out
to the Cambodian Pharmaceutical Enterprise (CPE), a
partly government owned pharmaceutical company, and
the social marketing of Malarine® has been contracted to
Population Services International (PSI).Malaria Journal 2008, 7:84 http://www.malariajournal.com/content/7/1/84
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Rapid diagnostic tests (RDTs)
Malaria transmission in Cambodia is generally low and
seasonal so a positive blood smear or positive RDT has a
high predictive value for infection with Plasmodium falci-
parum. One of the keystones of the new policy was the
provision of accurate biological diagnosis using RDTs
before treatment, to replace the inaccuracies of clinical
diagnosis. As around 90% of malaria in Cambodia was
due to P. falciparum, Paracheck® (Orchid Biomedical Sys-
tems), a P. falciparum – specific PfHRP2-based RDT was
introduced for use both in health centres without micro-
scopes and in the private sector alongside Malarine®. The
RDT was also used by trained village malaria workers
(VMWs) and malaria outreach teams (MOTs) as described
later.
Interventions to improve access to early diagnosis and 
appropriate treatment
In order to improve access to diagnosis and treatment, a
number of specific interventions were developed inde-
pendently by different organizations. This study describes
the cost of two of these interventions aimed at increasing
access to free or affordable diagnosis and treatment in the
community: Malaria Outreach Teams and Village Malaria
Workers.
Malaria Outreach Teams
Malaria outreach activities in Anlong Veng District, Oddor
Meanchey province were set-up, run and funded by
Médecins Sans Frontières (MSF) as part of their pro-
gramme of support in that area. This remote and heavily
forested area had remained a Khmer Rouge (KR) strong-
hold until 1999 and therefore lacked government-sup-
ported health facilities. The collapse of KR power resulted
in an influx of non-immune migrants from all over Cam-
bodia, who came in search of farmland and to collect for-
est products.
One of the major health problems as new settlers moved
into these areas were outbreaks of malaria. Between May
and August of 1999, in the health centre alone, there were
over 2000 confirmed malaria cases, 400 hospitalizations
and 18 deaths with malaria accounting for one third of all
outpatient and two thirds of all inpatient cases [14]. At the
time, the national antimalarial guidelines for uncompli-
cated P. falciparum malaria in that area was a single dose
of mefloquine (20 mg base/kg), and for complicated
malaria, quinine and tetracycline. In response to the out-
break and the known problem of drug resistance, MSF
switched first-line treatment to an ACT of artesunate and
mefloquine (A+M) and set up malaria outreach teams
(MOTs) consisting of teams of two people who went out
daily from the health centre to the settlements, in order to
diagnose and treat malaria using RDTs and A+M. There
were initially two teams, expanding to four teams with the
aim of visiting each settlement once or twice per week
depending on population movement, road conditions
and information about suspected malaria outbreaks. The
population of the district in 2001 was estimated to be
19,029 in 64 settlements (Goubert L, personal communi-
cation).
Village Malaria Workers (VMWs)
The first experience of using Village Malaria Workers in
Cambodia came from a community based trial for insec-
ticide treated bed nets (ITNs) in 30 villages in Rattanakiri
in the Northeast of the country in 2001. This is a remote,
heavily forested area, sparsely populated by ethnic minor-
ities, with low access to any kind of health service. Malaria
transmission in Rattanakiri is relatively high with cross-
sectional parasite prevalence rates of between five and
57% [15]. In order to address ethical concerns about hav-
ing a control group without any interventions, Village
Malaria Workers (VMW) were introduced in all villages.
The VMWs were trained to perform RDTs on any villagers
suspected of having malaria and to provide treatment as
per the national guidelines. They were supervised and re-
supplied monthly by the provincial malaria staff with sup-
port from the National Malaria Control Programme. The
resulting data from this passive surveillance system
exposed the scale of the malaria problem and demon-
strated that VMWs provided a practical means of access to
biological diagnosis and appropriate treatment. A further
pilot project was undertaken in 10 ethnic Khmer villages
in Koh Kong province in the South [16], and the scheme
has now been scaled up to cover 300 villages in 10 prov-
inces with funds from the Global Fund for AIDS, tubercu-
losis and malaria (GFATM) [17,18].
Table 1: Original dosage of artesunate (A) in 50 mg tablets and mefloquine (M) in 250 mg tablets*
Packages of artesunate and mefloquine Weight Age Day D1 D2 D3
Morning Evening
A+M2 16 – 24 kg 6 – 10 years 1M+1A 1M+1A 2A 2A
A+M3 25 – 34 kg 11 – 14 years 1M+1A 2M+2A 3A 3A
A+M4 35+ kg 15+ years 2M+2A 2M+2A 4A 4A
* The dosages are being modified in 2008Malaria Journal 2008, 7:84 http://www.malariajournal.com/content/7/1/84
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Costing
Costing was performed from the perspective of the pro-
vider. The incremental costs of the interventions are
described in order to aid generalization to other settings.
Costing was facilitated by the fact that the interventions
were specific to the change in policy to ACTs, and imple-
mented with new funds obtained for this purpose. Costs
were obtained from receipts, expenditure accounts, budg-
ets, logbooks and reports. Where these were not available,
estimates were obtained from WHO, MSF and CNM staff
who also provided estimates on time allocated to specific
interventions. Costing of the VMW intervention was
based on the Global Fund budget. The useful life of capital
goods was assumed to be six years for cars and five years
for all other goods, with costs annualized at a rate of 3%.
All costs were converted into US$ at an exchange rate of
US$1 = 3,900 Cambodian riel (which has remained stable
over the last seven to eight years).
The cost of blister packaging included the capital costs of
starting up the packaging facility (renovations, machin-
ery, consultancies and training), fixed recurrent costs
(overheads, maintenance and salaries) and those that var-
ied by production volume (packaging materials and
drugs). Actual expenditure on salaries for machine opera-
tors was not available and average monthly earnings in
the manufacturing industry in Cambodia were used.
The cost of RDTS included the cost of storage and wastage
due to spoilt and repeat test. In addition the cost of train-
ing and supervision costs were also estimated.
For the delivery interventions, the costs included the diag-
nostic tests and the blister-packaged drugs and the fixed
costs of each approach. The latter included the "basic"
fixed costs of training (including training materials, trans-
port and per diems for trainers and participants), over-
heads, transport and salaries. In addition the project start-
up costs and the cost of project co-ordinators were esti-
mated separately in order to facilitate comparison with
other settings. For each intervention, the level of activity
in terms of number of suspected malaria patients tested
and number of patients with falciparum malaria treated
was obtained in order to estimate the cost per case seen
and treated for each intervention. Both VMWs and MOTs
were closely supervised with cross-checking of RDT results
with drugs stocks ensuring that compliance to test results
was acceptable and that the practice of providing ACTs to
test-negative patients was minimized.
Results
The cost of the packaging materials and drugs is shown in
Table 2 and the total costs of the end-products are shown
in Table 3. The total costs of the blister-packaged drugs
were between $2.60 for the package for the A+M2 and
$3.77 for A+M4. The cost of Malarine® was slightly more
than A+M4 because of the higher cost of the artesunate
used (different dosage artesunate tablets were used, partly
in order to differentiate between the two types of prod-
ucts). The cost of packaging material was $0.09 per pack-
age for all packages. At the actual rate of production, the
salary cost was $0.34 per package and overhead costs
$0.71 per package, resulting in packaging cost alone of
$1.13 per package. If production were to increase to full
capacity, then the total cost of packaging would be
reduced more than five-fold to $0.19 per package, result-
ing in the total costs of A+M2 and A+M4 being considera-
bly lower, at $1.42 and $2.59 respectively. Figure 1 shows
that when the costs of the product are broken down, at the
current level of productivity, the drug costs accounted for
only 45% and 62% of the cost of A+M4 and A+M2 respec-
tively, compared to 83% and 90% at the desirable level of
productivity.
The basic cost of RDTs, inclusive of freight, storage and
wastage, was $0.83 for Paracheck®. Training was esti-
mated to cost $40.50 per health centre staff trained (based
on a one-day training course).
Tables 4 and 5 summarize the results of the cost analysis
for the MSF malaria outreach project and the VMW
scheme. It can be seen that excluding the cost of start-up
and co-ordinator, the annual fixed cost per capita of the
outreach scheme, at $0.44, was less than the VMW scheme
at $0.69. However, because a much smaller proportion of
the population was seen and treated by an outreach
worker than a VMW, the annual fixed costs per malaria
case treated for the latter was $5.14 compared to $12.74
Table 2: Cost of packaging and tablets
Cost of packaging1 Cost per blister (US$)
Aluminium foil 0.0267
PVC 0.0115
Individual boxes 0.0340
Large boxes (for 100 individual boxes) 0.0048
Ink for printing on box2 0.0020
Package insert 0.0010
Cost of drugs Cost per tablet (US$)3
Mefloquine 250 mg (Mepha®) 0.3696
Artesunate 50 mg (Gui Lin®) 0.0725
Artesunate 200 mg (Mepha ®) 0.3323
1The cost of the aluminium foil and PVC included freight and storage. 
Other products were available locally and the cost is the price paid 
inclusive of delivery and storage.
2Although the printing costs for the Malarine® products was higher 
than A+M because of the amount of coloured ink used, only an 
average cost of ink was available.
3Including 5% wastage and 3% freight.Malaria Journal 2008, 7:84 http://www.malariajournal.com/content/7/1/84
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in the malaria outreach scheme. Including start up costs
(annualized over five years), and the annual salary of co-
ordinators increased these estimates significantly, to
$7.48 for the VMW intervention and $21.12 for the
malaria outreach intervention.
Based on the activity data obtained from the outreach pro-
gramme and from the VMW pilot study, the total cost
inclusive of RDT and drug costs, was estimated. Assuming
that RDTs cost $0.83 per test and A+M cost $2.594 per
course, the total annual cost of the programmes was
$19.31 per capita for the outreach intervention and
$11.28 per capita for the VMW interventions (Table 5). If
drug costs were reduced to $1 per dose, the predicted cost
of dihydroartemisinin-piperaquine, then the total annual
costs would be approximately $17.72 and $9.69 per cap-
ita respectively.
Discussion
In this paper, the costs of interventions associated with
the roll-out of ACTs in Cambodia has been described in
order to assist countries which are now in the process of
implementing a change in policy to ACTs.
At the time when Cambodia change policy to artesunate
and mefloquine, there was not other choice than to co-
blister the drugs in a packaging facility developed specifi-
cally for that purpose. This study shows that at the ineffi-
ciencies of packaging at this scale were considerable. The
low productivity was due to a number of factors including
bottle-necks during the drug procurement process and the
inefficiencies related to small demand-based production.
Production has now been moved to Cambodian Pharma-
ceutical Enterprise, where staff can be moved to other pro-
duction lines when not working on A+M resulting in
greater efficiency. However, the local blister-packaging of
artesunate and mefloquine has not been straightforward
and much technical support has been required in order to
ensure that the packaging process is of acceptable quality.
This has resulted in critical delays and shortages in supply
and there is a consensus that a switch should be made a
soon as possible to a commercially packaged good-quality
co-formulated ACT.
Several commercially produced co-formulated ACTs are
now available for less than $2 including artemether-lume-
fantrine (Co-artem®) and dihydroartemisinin-piper-
aquine (Duo-Cotexcin®). Unfortunately artemether-
lumefantrine, which is the only co-formulated drug on
WHO's pre-qualification list, is relatively ineffective in
Cambodia [19]. On the other hand dihydroartemisinin-
piperaquine has been shown to be highly efficacious in
Cambodia and is a possible replacement for A+M for the
treatment of uncomplicated falciparum malaria [20]. Co-
formulated artesunate and mefloquine is unlikely to be
deployed because of a preference of switching to a new
combination with less side effects and lower levels of
resistance to the partner drug. For now, therefore, the rec-
ommended treatment in Cambodia continues to be blis-
ter-packaged artesunate and mefloquine.
From the cost analysis of delivery interventions, it is evi-
dent that interventions to increase access to treatment, can
incur substantial costs especially when start-up costs and
co-ordinator salaries are included. This is particularly the
case where programmes are malaria-specific and the inci-
dence of malaria is not that high, especially if staff are not
re-allocated to work on non-malarial problems in months
of low malaria transmission. The incremental costs
described in this analysis are probably particularly high
because of the limited infrastructure in the districts where
Table 3: Cost of blister-packaged artesunate and mefloquine
Drug package Actual cost (at 9.5% productivity) Potential cost (at full productivity)
Recurrent costs Recurrent and capital costs Recurrent costs Recurrent and capital costs
A+M2 (Art 50 mg × 6 + Mef 250 mg × 2) 2.307 2.595 1.386 1.420
A+M3* (Art 50 mg × 9 + Mef 250 mg × 3) 2.894 3.182 1.973 2.007
A+M4 (Art 50 mg × 12 + Mef 250 mg × 4) 3.480 3.769 2.560 2.594
Malarine® (adult) (Art 200 mg × 3 + Mef 250 mg × 
4)
3.608 3.896 2.688 2.722
*Same cost for Malarine junior ®
Breakdown in costs of blister-packaged drugs Figure 1
Breakdown in costs of blister-packaged drugs.
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these interventions took place and because malaria con-
trol management was still centralized. In neither case were
there pre-existing services for these remote communities.
In Anlong Veng, the outreach programme was based out
of the MSF-supported health centre which provided office
space and laboratory support for the malaria outreach
workers. For the VMW programme, the supervision and
re-supply of the VMWs was done both by the provincial
malaria supervisor and by staff from the CNM.
In comparing the two interventions, the fixed cost per case
tested and per case treated in the VMW scheme was almost
half the cost in the outreach scheme. This is because the
prevalence of malaria was higher in the area covered by
the VMW scheme in Rattanakiri from where the estimates
for the projected number of visits and cases came. The
VMWs were also more convenient and accessible than
outreach and were more often consulted. Recent data
from the scaled-up VMW intervention confirmed high
rates of consultation and high rates of parasite positivity
in symptomatic cases which would result in even lower
fixed costs per patient tested and treated [17]. In addition,
there are plans to broaden the remit of the VMWs so that
they can also treat diarrhoeal disease and acute respiratory
illness in children. Not only will this provide a more com-
prehensive service for the remote communities, but it will
also substantially improve the cost-effectiveness of the
intervention.
However, as explained, the populations covered by these
two interventions were quite different and it was felt that
VMWs would not have operated successfully in Anlong
Veng district because of the disparate and transient nature
of population. It cannot, therefore, be assumed that
VMWs are the more cost-effective option in all settings.
Nonetheless, the cost of the outreach programme, at
$12.74 per positive case, appeared to be considerably
more than that estimated by Ettling et al for a similar inter-
vention in Mae Sot, Thailand, where diagnosis was by
microscopy and treatment was with a single dose of
mefloquine [21]. Despite the slide positivity rate in Thai-
land being only 5%, the average provider cost per positive
case was equivalent to $2.57 and $0.13 per smear ($US1
(2005) = 35 baht (1990). It is not clear why there is such
large difference between the estimated costs of the two
programmes.
There have been a number of other descriptive studies of
Village Malaria Workers, however in most, costing data
were not available. One cost-minimization analysis was
performed on a small community based intervention in
Brazil. Volunteer bar owners in a remote mining town
were trained to use the ParaSight-F® test (a similar test to
Paracheck®) to diagnose malaria and to treat positive cases
with mefloquine monotherapy. The study compared the
direct costs (patient and provider) incurred with the inter-
Table 5: Estimated activity and cost of interventions per capita, 
per patient seen and per patient treated
Outreach VMW*
Population 19,029 100,000
Number seen and tested 3,152 57,360
Number P. falciparum cases treated 658 13,407
Basic annual fixed cost**
-per capita $0.44 $0.69
-per patient seen and tested $2.66 $1.20
-per PF patient treated $12.74 $5.14
Total annual cost (including test and 
drugs)
-per capita $0.67 $1.51
-per patient seen and tested $4.03 $2.64
-per PF patient treated $19.31 $11.28
*Based on estimates from pilot project and the Global Fund budget
**Without start-up and co-ordinator costs
Table 4: Summary of the annual fixed costs of the outreach and VMW interventions (not including RDTs and drugs)
Cost (US$)
Outreach VMW
Basic annual fixed running costs
(excluding expatriate co-ordinator and start-up)
Personnel (including cost of supervision) 5,422 20,270
Transport 2,224 37,850
Other (equipment, overheads) 739 10,738
Sub-total 8,385 68,858
Additional costs
Annual salary of co-ordinator (20% allocation for outreach, 100% for VMW) 4,643 24,000
Initial start-up cost annualized over 5 years (Total $4,710 for outreach and $40,000 for VMW) 869 7,384
Sub-total 5,512 31,384
Total annual cost 13,897 100,242Malaria Journal 2008, 7:84 http://www.malariajournal.com/content/7/1/84
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vention compared to the costs prior to the intervention,
when the main source of treatment was the government
clinic and hospital located 32 kilometres away. It was
found that net savings were $60,900 or $81 per person per
year [22,23].
It is important to recognize that the interventions
described here can both complement and substitute for
facility-based approaches. The choice and balance of dif-
ferent approaches needs to be tailored according to the
availability of resources and local conditions, and adapted
as the situation changes. In particular, malaria prevalence
will affect the relative efficiency of different strategies
[21,24]. In both the VMW scheme and the outreach
scheme, the nearest health centres provided co-ordina-
tion, support and supervision and were also essential in
being a place where patients could be referred to. It was
therefore important to ensure that these were functioning
well and that resources were allocated appropriately to
enable this to be the case.
There are few published data that include both the costs
and the effect of these interventions from the community
perspective. In a related paper, antimalarial drug usage
behaviour and household costs in areas with and without
VMWs and outreach clinics are compared in order to con-
tribute to the available literature [25].
Conclusion
As malaria-endemic countries start to roll-out ACTs and
the global community consider the setting up of a global
subsidy, it is important to consider the non-drug costs of
roll-out. If this includes the cost of packaging drugs
locally, then it is important to consider the efficiencies of
scale that result from producing larger volumes of pack-
aged drugs. Of even more importance is to consider the
need to access vulnerable communities and the substan-
tial additional investments required in order to reach
them via appropriate delivery systems such as village vol-
unteers. In addition, differences in local conditions, in
particular the prevalence of malaria and the pre-existing
infrastructure, should be considered in choosing appro-
priate diagnostic and delivery strategies. The costs of start-
ing-up projects and the expertise required for supervision
may be considerable and must be factored in when budg-
eting for scaling-up.
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